Pentoxifylline


Curated chemical-phenotype interactions from CTD
GO IDGO nameInteraction typeReference
GO:0000165 Mapk cascade Increases phenotype PMID:20804743
GO:0001836 Release of cytochrome c from mitochondria Increases phenotype PMID:37431890
GO:0006309 Apoptotic dna fragmentation Increases phenotype PMID:18851957; PMID:20804743
GO:0006915 Apoptotic process Affects phenotype PMID:14996430; PMID:18851957; PMID:20804743; PMID:33775688; PMID:9921918
GO:0006979 Response to oxidative stress Decreases phenotype PMID:16331539; PMID:18787510
GO:0007049 Cell cycle Increases phenotype PMID:7598686; PMID:8463339; PMID:9188632
GO:0008217 Regulation of blood pressure Increases phenotype PMID:14970111
GO:0008283 Cell population proliferation Decreases phenotype PMID:11788567; PMID:1709825; PMID:7598686
GO:0008284 Positive regulation of cell population proliferation Increases phenotype PMID:11843059
GO:0008285 Negative regulation of cell population proliferation Increases phenotype PMID:11843059
GO:0010942 Positive regulation of cell death Increases phenotype PMID:26851681
GO:0016042 Lipid catabolic process Increases phenotype PMID:36690085
GO:0016209 Antioxidant activity Decreases phenotype PMID:36690085
GO:0030154 Cell differentiation Increases phenotype PMID:7598686
GO:0030595 Leukocyte chemotaxis Increases phenotype PMID:1976392; PMID:3674202
GO:0034440 Lipid oxidation Increases phenotype PMID:29077241
GO:0042088 T-helper 1 type immune response Decreases phenotype PMID:7589090
GO:0042119 Neutrophil activation Increases phenotype PMID:19697996
GO:0042310 Vasoconstriction Decreases phenotype PMID:1411948
GO:0042311 Vasodilation Increases phenotype PMID:1411948; PMID:7528848
GO:0042391 Regulation of membrane potential Decreases phenotype PMID:8308680
GO:0042593 Glucose homeostasis Decreases phenotype PMID:29077241
GO:0043299 Leukocyte degranulation Affects phenotype PMID:17880773; PMID:1976392
GO:0044237 Cellular metabolic process Decreases phenotype PMID:33775688
GO:0044319 Wound healing, spreading of cells Decreases phenotype PMID:33775688
GO:0045333 Cellular respiration Increases phenotype PMID:19697996
GO:0046058 Camp metabolic process Affects phenotype PMID:37431890
GO:0046415 Urate metabolic process Decreases phenotype PMID:32777238
GO:0046449 Creatinine metabolic process Decreases phenotype PMID:32777238
GO:0046466 Membrane lipid catabolic process Decreases phenotype PMID:15932791
GO:0046649 Lymphocyte activation Decreases phenotype PMID:17880773
GO:0048266 Behavioral response to pain Decreases phenotype PMID:37431890
GO:0051881 Regulation of mitochondrial membrane potential Affects phenotype PMID:18851957; PMID:20620236; PMID:37431890
GO:0070301 Cellular response to hydrogen peroxide Increases phenotype PMID:29077241
GO:0072593 Reactive oxygen species metabolic process Affects phenotype PMID:33775688
GO:1903283 Negative regulation of glutathione peroxidase activity Increases phenotype PMID:29077241
GO:2000562 Negative regulation of cd4-positive, alpha-beta t cell proliferation Increases phenotype PMID:25433234
DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.